Table 3.
Descriptors of disease activity | Number (%) (n = 1846) |
---|---|
1. SLEDAI-2 K ≤4, with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis, haemolytic anaemia, fever) and no gastrointestinal activity | 1171 (63.43 %) |
2. No new features of lupus disease activity compared to the previous assessment | 1574a (85.27 %) |
3. SELENA-SLEDAI Physician Global Assessment (PGA, scale 0–3) ≤1 | 1400 (75.84 %) |
Immunosuppressive medications | |
4. Current prednisolone (or equivalent) dose ≤7.5 mg daily | 1258 (68.15 %) |
5. Well-tolerated standard maintenance doses of immunosuppressive drugs and approved biologic agents, excluding investigational drugsb | 1838 (99.57 %) |
All 5 criteria present | 810 (43.88 %) |
aBased on flares (see “Methods”). bCalculated as not exceeding maximum recommended dose: hydroxychloroquine ≤400 mg; methotrexate ≤30 mg; azathioprine ≤200 mg; mycophenolate mofetil ≤3000 mg; mycophenolic acid ≤2160 mg; leflunomide ≤20 mg. SLE systemic lupus erythematosus, SELENA Safety of Estrogens in Lupus Erythematosus National Assessment trial, SLEDAI SLE disease activity index, CNS central nervous system, PGA Physician Global Assessment